Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.

Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD

StockBot

416,823 posts

MSB released this announcement to the ASX on 7 December 2020, 8:48. The announcement is not marked as price sensitive, and is 2 page(s) in length and 146.6kb in size.

You can view all announcements from MSB and see how they appear on a price chart on the announcements page.

At the date of this announcement, MSB was 7.820% short sold according to ASIC data. It was ranked the 12th most shorted stock on the ASX. It remains ranked 40th as of the latest reported data (05 May 2025).

Other Recent Announcements from MSB
Change of Director's Interest Notice 13 June 2023, 8:56
Mesoblast Director Appointed to Strategic Advisory Role 5 June 2023, 9:41
MSB Reports Q3 Financial Results and Operational Highlights 26 May 2023, 8:32
Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD 7 December 2020, 8:48
Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS 2 December 2020, 9:08
Appendix 2A 27 November 2020, 17:15
Results of Meeting 24 November 2020, 13:33
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track MSB and receive email alerts.